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ORIGINAL ARTICLE

Constitutively activated PI3K accelerates tumor initiation
and modiﬁes histopathology of breast cancer
MR Sheen1, JD Marotti2,3,4, MJ Allegrezza5, M Rutkowski5, JR Conejo-Garcia5 and S Fiering1,4,6
The gene encoding phosphatidylinositol 3-kinase catalytic subunit α-isoform (PIK3CA, p110α) is frequently activated by mutation in
human cancers. Based on detection in some breast cancer precursors, PIK3CA mutations have been proposed to have a role in
tumor initiation. To investigate this hypothesis, we generated a novel mouse model with a Cre-recombinase regulated allele of
p110α (myristoylated-p110α, myr-p110α) along with p53ﬂ/ﬂ deletion and KrasG12D also regulated by Cre-recombinase. After
instillation of adenovirus-expressing Cre-recombinase into mammary ducts, we found that myr-p110α accelerated breast tumor
initiation in a copy number-dependent manner. Breast tumors induced by p53ﬂ/ﬂ;KrasG12D with no or one copy of myr-p110α had
predominantly sarcomatoid features, whereas two copies of myr-p110α resulted in tumors with a carcinoma phenotype. This novel
model provides experimental support for importance of active p110α in breast tumor initiation, and shows that the amount of PI3K
activity can affect the rate of tumor initiation and modify the histological phenotype of breast cancer.
Oncogenesis (2016) 5, e267; doi:10.1038/oncsis.2016.65; published online 31 October 2016

INTRODUCTION
Receptor tyrosine kinase-phosphatidylinositol 3-kinase (PI3K)
signaling is a central integrator of metabolism, cell growth
and cell survival, and deregulated PI3K signaling increases
tumorigenicity.1,2 Cancer-associated mutations occur in several
components of the pathway including activating mutations of
both the PI3K catalytic subunit α-isoform gene (PIK3CA, p110α)3
and the downstream signaling molecule AKT1,4 as well as deletion
of the negative pathway regulator, PTEN.5 These alterations all
result in increased activity of the PI3K signaling pathway. The
signiﬁcance of p110α in cancer is demonstrated by the high
frequency of activating mutations in many common human
cancers that increase the catalytic activity of PI3K.3,6
High-throughput RNA sequencing and tumor resequencing
have revealed that hyperactivating mutations in the PI3K signaling
pathway occur in a substantial percentage of breast cancers.7 The
PIK3CA gene itself, encoding the p110α catalytic subunit, is the
most frequently mutated gene in breast cancer,8,9 with mutations
in 25–40% of all breast cancers.10,11 However, the prognostic
implications of p110α mutations remain unclear. Although the
association of PI3K mutations with poor prognosis has been
reported,12,13 others have described a correlation with improved
outcome.14,15
Whole-exome analysis of ﬁnely dissected and matched
mammary tumors has shown that alterations in the p110α gene
are detected at the same frequencies in ductal carcinoma in situ
(DCIS), DCIS adjacent to invasive carcinoma and invasive
carcinoma.16 In addition, the p110α sequences are often found
to be identical in invasive and in situ areas of the same breast
tumor.16 This pattern of mutation suggests that p110α mutations
are a relatively early event in breast cancer development. In light
of these ﬁndings, mutational activation of the PI3K signaling

pathway has been proposed to have a role in breast tumor
initiation.
Multiple mouse models of the PI3K pathway-driven cancer have
recently been developed to investigate the impact of PI3K
mutation or combination of other related mutations on breast
cancer development under the control of MMTV LTR or WAP
promoter.17–21 However, the role of PI3K activation in tumor
initiation, progression and phenotype is not well understood. In
the present study, the PI3K catalytic subunit p110α was
myristoylated to force localization to the cell membrane, which
is sufﬁcient to release its kinase activity from normal regulation,
and to thus activate the PI3K signaling pathway. The expression of
myristoylated-p110α was regulated by Cre-recombinase expressed
from Ad-Cre virus, which allowed for spatial and temporal
experimental control. To ascertain the impact of p110α activating
mutations in tumor initiation and progression, we combined
myr-p110α with frequently co-occurring mutations of two genes,
p53 and Kras, to generate novel models of breast, lung and
potentially other cancers whose induction is controlled by the
researcher.
RESULTS
In vivo expression of myr-p110α and homozygous p53 deletion in
milk duct causes slowly developing mammary tumors
To elucidate the role of activating mutations of p110α
in tumorigenesis, we engineered a mouse with conditional
myristoylated-p110α (myr-p110α) ubiquitously expressed from
the Rosa26 locus (Supplementary Figure 1).22 Constitutive expression of myr-p110α during development was embryonic lethal.22
To have temporal and spatial control over tumorigenic genetic
changes in breast cancer, we utilized in vivo administration of
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adenovirus-expressing Cre-recombinase (Ad-Cre) into the
mammary duct of virgin females.23
As activated myr-p110α by itself had minimal transforming
activity (Supplementary Figure 2) and the p53 gene is the second
most frequently mutated gene in breast cancer,8,24 we assessed
the effect of myr-p110α and homozygous p53 deletion on breast
tumor development. In line with its tumorigenic potential in

mouse embryonic ﬁbroblasts (MEFs; Supplementary Figure 2)
and previous studies showing the cooperation between
Pik3caH1047R activating mutation and p53 knockout in vivo,17,20
mice expressing one copy of myr-p110α and homozygous for
p53 deletion (p53ﬂ/ﬂ;myr-p110αwt/ﬂ) developed mammary tumors
with 100% penetrance but with a long latency (mean tumor onset
259.6 ± 10.6 days; Figure 1a). Histological analysis of the tumors
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revealed predominantly poorly differentiated or dedifferentiated
malignant neoplasms with sarcomatoid features as well as small
areas of high-grade carcinoma. The sarcomatoid neoplasms were
positive for estrogen receptor α (ERα), focal progesterone receptor
(PR) and vimentin (mesenchymal marker); they were negative for
cytokeratin 5 (CK5, basal epithelial marker), cytokeratin 14 (CK14,
myoepithelial marker), cytokeratin 8 (CK8, luminal epithelial
marker) and human epidermal growth factor receptor 2
(Her2/neu; Figure 1b). In contrast, mice harboring either
myr-p110αwt/ﬂ or homozygous p53 deletion only, failed to form
mammary tumors during 12 months of observation.
Mammary tumors expressing p53ﬂ/ﬂ;myr-p110αwt/ﬂ activate PI3K
signaling
Increased PI3K signaling activates AKT, a key downstream effector
of PI3K signaling pathway.25 To test for PI3K signaling activation,
mammary tumors were analyzed for levels of total p110α, total
AKT, the active phosphorylated form of AKT (p-AKT), PI3K
regulatory subunit p85α, PI3K negative regulator PTEN and the
less active phosphorylated form of PTEN with reduced lipid
phosphatase activity (p-PTEN).26,27 As compared with normal
mammary tissue, mammary tumors from p53ﬂ/ﬂ;myr-p110αwt/ﬂ
females had elevated levels of total p110α (32-fold), p-AKT
(37-fold) and p-AKT/AKT ratio (34-fold; Figures 1c and d).
Expression of myr-p110α was conﬁrmed by the detection of GFP
in mammary tumors (Figure 1c). The p53ﬂ/ﬂ;myr-p110αwt/ﬂ
mammary tumors also displayed signiﬁcantly increased total
protein levels of p85α (1.9-fold), PTEN (1.3-fold) and p-PTEN
(1.7-fold; Figures 1e and f), suggesting naturally occurring
negative feedback mechanisms to inhibit abnormal PI3K activity
driven by myr-p110α. Elevated levels of p-AKT were associated
with the increased PI3K activity despite increased levels of PI3K
regulators, p85α and PTEN, demonstrating ineffective regulation
by increased p85α and PTEN.
Addition of myr-p110α into p53ﬂ/ﬂ;KrasG12D double mutants
accelerates mammary tumor initiation but not tumor growth rate
It has been proposed that PIK3CA has a role in tumor initiation,
as its mutations are detected in precursors of breast cancer.28
To investigate the role of myr-p110α in tumor initiation and
progression, we exploited the Cre-inducible oncogenic mouse
model p53ﬂ/ﬂ;KrasG12D, which harbors a homozygous p53 deletion
and a KrasG12D activating missense allele that rapidly grows
tumors.29 Based on the published breast cancer genomics data,
KrasG12D mutation tends to co-occur with p53 mutations
(Supplementary Figures 3A and 3B). To assess tumor initiation
and development in p53ﬂ/ﬂ;KrasG12D mice in the absence or
presence of myr-p110α, mice harboring p53ﬂ/ﬂ;KrasG12D or p53ﬂ/ﬂ;
KrasG12D;myr-p110αwt/ﬂ were generated. Ad-Cre virus was administered into the milk duct of virgin females and mice were

monitored for initial tumor formation and growth rate. Both
p53ﬂ/ﬂ;KrasG12D and p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice developed
mammary tumors with 100% penetrance. Notably, although
p53ﬂ/ﬂ;KrasG12D mice began to form palpable mammary tumors
(tumor size ranges 12–15 mm2) with a mean tumor onset of
54.8 ± 0.7 days, p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice started to form
palpable mammary tumors with a mean tumor onset of
28.7 ± 0.4 days (Figure 2a), indicating roughly two-fold acceleration of tumor initiation due to expression of myr-p110α.
To examine the difference in tumor progression, the period of
tumor growth was deﬁned as the number of days between when
a mammary tumor was ﬁrst observed and when the animal
reached end point, and depicted in the Kaplan–Meier survival
curve. Although initiation was markedly accelerated, once the
tumor was established, there was no difference in tumor growth
rate between p53ﬂ/ﬂ;KrasG12D and p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ
mice. Mammary tumors from p53ﬂ/ﬂ;KrasG12D mice reached end
point with a mean of 18.7 ± 0.7 days, and p53ﬂ/ﬂ;KrasG12D;
myr-p110αwt/ﬂ mammary tumors reached end point with a mean
of 18.4 ± 0.5 days (Figure 2b).
Mammary tumors from p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ have higher
p-AKT levels than those from p53ﬂ/ﬂ;KrasG12D
To biochemically characterize mammary tumors from p53ﬂ/ﬂ;
KrasG12D and p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ, we tested the PI3K
pathway activation status of the mammary tumors by analyzing
the levels of p110α, AKT, p-AKT, p85α, PTEN and p-PTEN.
Mammary tumors from p53ﬂ/ﬂ;KrasG12D females had signiﬁcantly
elevated levels of total p110α (4.5-fold), p-AKT (11-fold) and
p-AKT/AKT ratio (10-fold) as shown in Figures 2c and d, in
comparison with normal mammary tissue. p53ﬂ/ﬂ;KrasG12D;
myr-p110αwt/ﬂ mammary tumors with one copy of myr-p110α
had further elevated expression levels of total p110α (39-fold), and
this resulted in increased p-AKT levels by 48-fold and increased
p-AKT/AKT ratio (52-fold; Figures 2c and d). Expression of
myr-p110α via Ad-Cre virus injection was conﬁrmed by GFP
expression in p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mammary tumors
(Figure 2c).
Mammary tumors from p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice had
elevated accumulation of regulatory subunit p85α by two-fold as
compared with normal mammary tissue, whereas p53ﬂ/ﬂ;KrasG12D
mammary tumors displayed signiﬁcantly decreased p85α level
(0.6-fold) as shown in Figures 2e and f. The PTEN levels had a
modest but statistically signiﬁcant 0.6-fold decrease in p53ﬂ/ﬂ;
KrasG12D mammary tumors compared with normal mammary
tissue (Figures 2e and f). The ratios of p-PTEN/PTEN were slightly
but signiﬁcantly increased in p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ
(1.3-fold) mammary tumors (Figure 3f), indicating overall increase
of less active p-PTEN.

Figure 1. In vivo expression of myr-p110α and homozygous p53 deletion in milk duct activates PI3K signaling and develops mammary tumors.
(a) Kaplan–Meier survival curve demonstrating breast tumor onset deﬁned as the ﬁrst palpation-mediated recognition of tumors (n = 10 per
group). Log-rank (Mantel–Cox) test was used for statistical analysis. ***Po0.001. (b) Hematoxylin and eosin (H&E) staining and
immunohistochemistry of mammary tumors from p53ﬂ/ﬂ;myr-p110αwt/ﬂ females stained with antibodies against following markers: ERα
(estrogen receptor α), PR (progesterone receptor), vimentin (mesenchymal marker), CK5 (basal marker), CK14 (myoepithelial marker), CK8
(luminal marker) and Her2/neu. Representative pictures of H&E staining and immunostaining were taken with × 200 magniﬁcation. Scale bar
100 μm indicates scale for all images. The poorly differentiated neoplasm is immunoreactive with ERα and vimentin, and negative for the
remaining antigens. A normal duct serves as an internal control (arrow in H&E). (c) Western blot analysis of p110α, p-AKT, AKT and GFP with
normal mammary tissue and mammary tumors from p53ﬂ/ﬂ;myr-p110αwt/ﬂ mice. (d) The graphs of western blot signals of p110α, p-AKT and
p-AKT/AKT ratio quantiﬁed and normalized with respect to β-actin. (e) Western blot analysis of p85α, p-PTEN and PTEN with wild-type
mammary tissue and p53ﬂ/ﬂ;myr-p110αwt/ﬂ mammary tumors. (f) The graphs of western blot signals of p85α, p-PTEN, PTEN and p-PTEN/PTEN
ratio quantiﬁed and normalized with respect to β-actin. For d and f, mean fold increase compared with mammary tissue lysates from a nonCre harboring age-matched female was calculated after normalization. Error bars are the mean ± s.e.m. Two-tailed unpaired Student’s t-test
was used for statistical analysis. *P o0.05, **P o0.01 and ***P o0.001. Data in c–f are representative of four independent experiments with
biological and technical replicates.
Oncogenesis (2016), 1 – 11
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Figure 2. Addition of myr-p110α into p53ﬂ/ﬂ;KrasG12D double mutants increases PI3K signaling and accelerates mammary tumor initiation with no
impact on tumor growth rate. (a) Kaplan–Meier survival curve demonstrating breast tumor onset in the two strains. Log-rank (Mantel–Cox) test was
used for statistical analysis. ***Po0.001. (b) Kaplan–Meier survival curve demonstrating mammary tumor progression in each strain. The period of
tumor growth was deﬁned as the number of days between when a mammary tumor was ﬁrst observed in the size range of
12–15 mm2 and when tumor surface area reached the end point of 100 mm2. Log-rank (Mantel–Cox) test was used for statistical analysis.
P40.05, non-signiﬁcant. (c) Western blot analysis of p110α, p-AKT, AKT and GFP with wild-type (WT) mammary tissue and mammary tumors from
p53ﬂ/ﬂ;KrasG12D and p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice. (d) The graphs of western blot signals of p110α, p-AKT, p-AKT/AKT ratio and AKT quantiﬁed and
normalized with respect to β-actin. (e) Western blot analysis of p85α, p-PTEN and PTEN with WT mammary tissue and mammary tumors from p53ﬂ/ﬂ;
KrasG12D and p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice. (f) The graphs of western blot signals of p85α, p-PTEN, PTEN and p-PTEN/PTEN ratio quantiﬁed and
normalized with respect to β-actin. Mean fold increase compared with mammary tissue lysates from a non-Cre harboring age-matched female was
calculated after normalization. Error bars are the mean ± s.e.m. Two-tailed unpaired Student’s t-test was used for statistical analysis. *Po0.05,
**Po0.01 and ***Po0.001. Data in c–f are representative of four independent experiments with biological and technical replicates.

Two copies of myr-p110α further accelerate mammary tumor
initiation and promote tumor progression
To determine how doubling the copy number of myr-p110α would
impact tumorigenesis in this breast cancer model, we generated
homozygous mice with two copies of myr-p110α transgene along
with p53ﬂ/ﬂ;KrasG12D mutants (p53ﬂ/ﬂ;KrasG12D;myr-p110αﬂ/ﬂ). After
Ad-Cre virus administration into the milk duct of virgin females,
the time of tumor onset and tumor growth rate of p53ﬂ/ﬂ;KrasG12D;
myr-p110αﬂ/ﬂ mammary tumors were compared with those of
p53ﬂ/ﬂ;KrasG12D and p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mammary
tumors to assess the effect of homozygous myr-p110α alleles.
Intraductal delivery of Ad-Cre virus into p53ﬂ/ﬂ;KrasG12D;
myr-p110αﬂ/ﬂ mice induced the development of mammary tumors
Oncogenesis (2016), 1 – 11

with 100% penetrance and a mean tumor onset of 15.7 ± 0.6 days
(Figure 3a). This tumor initiation was much faster than
p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice (one copy of myr-p110α,
28.7 ± 0.4 days) and p53ﬂ/ﬂ;KrasG12D mice (zero copy of
myr-p110α, 54.8 ± 0.7 days). In accordance with this result, addition
of two copies of myr-p110α into homozygous p53 deletion (p53ﬂ/ﬂ;
myr-p110αﬂ/ﬂ) also facilitated mammary tumor initiation compared
with p53ﬂ/ﬂ;myr-p110αwt/ﬂ (135.1 ± 6.2 days vs 259.6 ± 10.6 days;
Figure 3b).
To check whether there would be a correlation between the
extent of PI3K signaling activation and the rate of tumor initiation,
we evaluated the PI3K signaling activation status by comparing
the levels of p-AKT between p53ﬂ/ﬂ;myr-p110αwt/ﬂ, p53ﬂ/ﬂ;
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Figure 3. Two copies of myr-p110α further increase PI3K activity and accelerate mammary tumor initiation and growth rate. (a) Kaplan–Meier
survival curve demonstrating the breast tumor onset in three strains: p53ﬂ/ﬂ;KrasG12D, p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ and p53ﬂ/ﬂ;KrasG12D;
myr-p110αﬂ/ﬂ. (b) Kaplan–Meier survival curve demonstrating the breast tumor onset in three strains: p53ﬂ/ﬂ, p53ﬂ/ﬂ;myr-p110αwt/ﬂ and p53ﬂ/ﬂ;
myr-p110αﬂ/ﬂ. (c) Western blot analysis of p110α, p-AKT and AKT with mammary tumors from p53ﬂ/ﬂ;myr-p110αwt/ﬂ, p53ﬂ/ﬂ;myr-p110αﬂ/ﬂ, p53ﬂ/ﬂ;
KrasG12D;myr-p110αwt/ﬂ and p53ﬂ/ﬂ;KrasG12D;myr-p110αﬂ/ﬂ mice. (d) The graphs of western blot signals of p110α, p-AKT and p-AKT/AKT ratio
quantiﬁed and normalized with respect to β-actin. Mean fold increase compared with p53ﬂ/ﬂ;myr-p110αwt/ﬂ mammary tumors was calculated after
normalization. Error bars are the mean ± s.e.m. Two-tailed unpaired Student’s t-test was used for statistical analysis. *Po0.05, **Po0.01 and
***Po0.001. Data in c and d are representative of three independent experiments with biological and technical replicates. (e) Kaplan–Meier
survival curve demonstrating mammary tumor progression in three strains: p53ﬂ/ﬂ;KrasG12D, p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ and p53ﬂ/ﬂ;KrasG12D;
myr-p110αﬂ/ﬂ. The period of tumor growth was deﬁned as the number of days between when a mammary tumor was ﬁrst observed in the size
range of 12–15 mm2 and when tumor size reached 100 mm2. For a, b and e, Log-rank (Mantel–Cox) test was used for statistical analysis with
**Po0.01 and ***Po0.001. To determine whether copy number increase in myr-p110α would have further impact on tumor initiation and
progression in breast cancer models, the data generated from p53ﬂ/ﬂ;KrasG12D and p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ females shown in the Figures 2a
and b, and the data generated from p53ﬂ/ﬂ and p53ﬂ/ﬂ;myr-p110αwt/ﬂ females shown in the Figure 1a, were replicated for comparison.

myr-p110αﬂ/ﬂ, p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ and p53ﬂ/ﬂ;KrasG12D;
myr-p110αﬂ/ﬂ mammary tumors. Two copies of myr-p110α
signiﬁcantly elevated levels of total p110α (1.9-fold) and p-AKT
(2.1-fold), as compared with one copy of myr-p110α (Figures 3c
and d). We also tested the extent of PI3K signaling activation in
mammary tumors harboring zero, one or two copies of myr-p110α
transgene combined with either p53ﬂ/ﬂ or p53ﬂ/ﬂ;KrasG12D mutants.
The levels of PI3K signaling activation were signiﬁcantly elevated
in a myr-p110α copy number-dependent manner (Supplementary

Figure 4). These data demonstrate that a single copy of myr-p110α
does not saturate the PI3K signaling pathway with regard to p-AKT
levels and two copies of myr-p110α further activate PI3K signaling
to a greater degree than that induced by a single copy of
myr-p110α in mammary tumors, resulting in the increased rate of
tumor initiation.
As the rate of tumor initiation was further inﬂuenced by the
addition of KrasG12D mutation into p53ﬂ/ﬂ;myr-p110α, which has
been shown to signal primarily through the PI3K/AKT pathway,30
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Figure 4. Addition of myr-p110α allele into p53ﬂ/ﬂ;KrasG12D double mutants modiﬁes tumor histology in a copy number-dependent manner.
(a) Representative hematoxylin and eosin (H&E) sections of mammary tumors from p53ﬂ/ﬂ;KrasG12D, p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ and p53ﬂ/ﬂ;
KrasG12D;myr-p110αﬂ/ﬂ mice showing increasing epithelial differentiation with addition of myr-p110α allele. Scale bar represents 0.5 mm and
indicates scale for all images. (b) Comparison of histologic and immunohistochemical (CK8, ERα, PR and vimentin) phenotypes between p53ﬂ/ﬂ;
KrasG12D and p53ﬂ/ﬂ;KrasG12D;myr-p110αﬂ/ﬂ tumors. Representative H&E sections show solid sheets and fascicles of pleomorphic spindle cells in
p53ﬂ/ﬂ;KrasG12D tumor compared to the epithelial nests and glands present in p53ﬂ/ﬂ;KrasG12D;myr-p110αﬂ/ﬂ tumor. Both tumors are
immunoreactive with CK8 and ERα; the p53ﬂ/ﬂ;KrasG12D tumor is PR negative and vimentin positive, whereas the p53ﬂ/ﬂ;KrasG12D;myr-p110αﬂ/ﬂ
tumor is PR positive and vimentin negative. Scale bar represents 100 μm. Magniﬁcation is × 40 (a), × 400 (ERα staining of the p53ﬂ/ﬂ;KrasG12D
tumor in b) or × 200 (all remaining images in b).

we assessed the levels of PI3K signaling activation in p53ﬂ/ﬂ;
myr-p110α mammary tumors with or without KrasG12D mutation.
Mammary tumors from p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ and p53ﬂ/ﬂ;
KrasG12D;myr-p110αﬂ/ﬂ had signiﬁcantly increased levels of total
p110α (1.3-fold) and p-AKT levels (1.3-fold), as compared with
p53ﬂ/ﬂ;myr-p110αwt/ﬂ and p53ﬂ/ﬂ;myr-p110αﬂ/ﬂ mammary tumors as
shown in Figures 3c and d. These ﬁndings show that PI3K
signaling can be further activated by cooperation of myr-p110α
with KrasG12D mutation, and the rate of tumor initiation is strongly
inﬂuenced by the level of PI3K activity.
Interestingly, the addition of two copies of myr-p110α also
modestly but signiﬁcantly accelerated tumor progression, as
revealed by the survival curve (Figure 3e). Mammary tumors from
p53ﬂ/ﬂ;KrasG12D;myr-p110αﬂ/ﬂ mice reached end point with a mean
of 15.4 ± 0.8 days, faster than p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice
(18.4 ± 0.5 days) and p53ﬂ/ﬂ;KrasG12D mice (18.7 ± 0.7 days).
Oncogenesis (2016), 1 – 11

Addition of myr-p110α into p53ﬂ/ﬂ;KrasG12D double mutants
modiﬁes histologic phenotype
Given the inherent heterogeneity of breast cancers, mammary
tumors from the transgenic mice were characterized histologically
(Figure 4). Mammary tumors from p53ﬂ/ﬂ;KrasG12D mice were
mostly poorly differentiated malignant neoplasms with sarcomatoid features. Mammary tumors from p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ
also had a predominantly sarcomatoid histologic phenotype
similar to p53ﬂ/ﬂ;KrasG12D mammary tumors, but ~ 10–15% of
tumor area was better differentiated with overt epithelial
components including DCIS, papillary carcinoma and invasive
ductal carcinoma.
Histological analysis of mammary tumors from p53ﬂ/ﬂ;KrasG12D;
myr-p110αﬂ/ﬂ mice demonstrated an increase in tumors with a
carcinoma phenotype including both DCIS and invasive ductal
carcinoma (Figure 4a). It was also noted that there was an increase
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Addition of myr-p110α into p53ﬂ/ﬂ;KrasG12D increases metastatic
potential
To assay the ability of breast tumor cells to establish tumors
outside the breast, we derived cells from p53ﬂ/ﬂ;KrasG12D, p53ﬂ/ﬂ;
KrasG12D;myr-p110αwt/ﬂ and p53ﬂ/ﬂ;KrasG12D;myr-p110αﬂ/ﬂ mammary
tumors, introduced them into the circulation by tail vein injection
into syngeneic mice, and monitored for the formation of breast
tumors in the lungs, as this method is considered to be a relevant
model for breast cancer lung metastasis.31 17 days after injection,
mice injected with the p53ﬂ/ﬂ;KrasG12D;myr-p110αﬂ/ﬂ breast tumor
cells produced signiﬁcantly more identiﬁable tumors in the lungs
(mean 318.6 ± 7.4) compared with mice injected either with p53ﬂ/ﬂ;
KrasG12D breast tumor cells (mean 6.3 ± 2.6) or p53ﬂ/ﬂ;KrasG12D;
myr-p110αwt/ﬂ breast tumor cells (mean 206.1 ± 10.0; Figure 5). This
suggests that the myr-p110α promotes growth of metastatic
tumors in a copy number-dependent manner.
Addition of myr-p110α allele into p53ﬂ/ﬂ;KrasG12D double mutants
accelerates tumor initiation in lung and decreases survival
One intentional aspect of the generation of this Cre-inducible
mouse model and the utilization of Ad-cre virus is the ability to
genetically modify different anatomic locations and potentially
cause different tumor types. For the generation of lung cancer, we
utilized injection of Ad-Cre virus into the trachea without surgery.
Both p53ﬂ/ﬂ;KrasG12D and p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice
developed lung tumors with 100% penetrance. Histological
analysis of lung tumors 52 days after intratracheal injection
of Ad-Cre virus (when the ﬁrst mice had symptoms of lung
tumor growth) revealed high-grade adenocarcinomas that were
largely disseminated throughout the lungs of p53ﬂ/ﬂ;KrasG12D;
myr-p110αwt/ﬂ mice, whereas p53ﬂ/ﬂ;KrasG12D mice developed only
focal, small areas of adenocarcinoma (Figure 6a). Accordingly,
lungs from p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice were enlarged and
weighed two to three times more than lungs from either p53ﬂ/ﬂ;
KrasG12D mice or non-tumor-bearing mice, deﬁning more tumor
burdens (Figure 6b). These ﬁndings indicate that the addition of
myr-p110α promotes lung tumor development. In contrast with
breast cancer, the addition of one copy of myr-p110α into p53ﬂ/ﬂ;

p53fl/fl;KrasG12D, n=8
p53fl/fl;KrasG12D;myr-p110

wt/fl,

p53fl/fl;KrasG12D;myr-p110

fl/fl,

***

400
No. of lung tumor lesions

in benign epithelial proliferations including adenosis and papillomas. Some of the tumors had an admixed spindle cell component.
As the copy number of myr-p110α doubled, the majority of p53ﬂ/ﬂ;
myr-p110αﬂ/ﬂmammary tumors also developed a carcinoma
phenotype, whereas p53ﬂ/ﬂ;myr-p110αwt/ﬂ mammary tumors
developed dedifferentiated mixed tumors with sarcomatoid
features and only focal areas of carcinoma (Supplementary
Figure 5). These ﬁndings show that increased PI3K activity
mediated by two copies of myr-p110α, when combined with
either p53ﬂ/ﬂ or p53ﬂ/ﬂ;KrasG12D, have the potential to skew
mammary tumors from a sarcomatoid phenotype to a carcinoma
phenotype more common in humans.
As part of the pathological characterization, tumors were
stained for the following markers: CK5, CK14, CK8, ERα, PR,
Her2/neu and vimentin. The majority of mammary tumors
(invasive and in situ carcinoma, and benign proliferations) from
p53ﬂ/ﬂ;KrasG12D;myr-p110αﬂ/ﬂ mice displayed strong CK8, ERα and
PR immunostaining (Figure 4b). They were negative for vimentin
(Figure 4b), whereas CK5 and CK14 immunostains conﬁrmed the
presence of myoepithlelial cells within DCIS and benign epithelial
proliferations (data not shown). The sarcomatoid tumors from
p53ﬂ/ﬂ;KrasG12D mice were strongly positive for vimentin and
showed variable expression of CK8, ERα and PR (Figure 4b). They
were negative for CK5 and CK14. Tumors from p53ﬂ/ﬂ;KrasG12D;
myr-p110αwt/ﬂ mice displayed greater immunostaining for
CK8 compared to p53ﬂ/ﬂ;KrasG12D mice (data not shown). None
of the tumors from the three groups demonstrated positive (3+)
Her2/neu immunostaining.

350
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n=8
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***

200
150
100
50
0
17 days post intravenous injection of
breast tumor cells

Figure 5. Combination of myr-p110α with p53ﬂ/ﬂ;KrasG12D increases
metastatic potential in a myr-p110α copy number-dependent
manner. The graph showing the number of tumor lesions found
in the lung surface 17 days after intravenous injection of breast
tumor cells with different genotypes into the tail vein of syngeneic
hosts. Error bars are the mean ± s.e.m. Two-tailed unpaired Student’s
t-test was used for statistical analysis. ***P o0.001. In parallel,
Mann–Whitney test (Wilcoxon rank-sum test) was used to reject the
null hypothesis that there is no difference between groups
(***Mann–Whitney U-value = 0.0009). Data are representative of
three independent experiments using n = 8 per group with
biological and technical replicates. Six- to eight-week-old syngeneic
host mice were randomly assigned to generate similar numbers of
subjects among groups.

KrasG12D did not change histology of the lung tumors. To further
deﬁne the characteristics of the lung tumor development, mice
were allowed to reach end point. The mean survival of p53ﬂ/ﬂ;
KrasG12D;myr-p110αwt/ﬂ mice was 55 ± 1.4 days, whereas the mean
survival of p53ﬂ/ﬂ;KrasG12D mice was 112 ± 1.6 days, (Figure 6c). This
ﬁnding was similar to the breast tumor experiments, in which
survival time was cut in half by addition of one copy of myr-p110α.
Overall, our observations demonstrate that the addition of
constitutively active myr-p110α allele causes early tumor initiation
in the lung, leading to early death related to lung tumors.
DISCUSSION
Impact of constitutively active PI3K on tumor initiation and
progression
It has recently been shown that cell signaling in many breast
cancers is associated with an activated PI3K/AKT pathway.32
Notably, by evaluating differences in the p-AKT levels between
mammary tumors harboring zero, one or two copies of myr-p110α
allele combined with either p53ﬂ/ﬂ or p53ﬂ/ﬂ;KrasG12D mutants, our
results proved that the levels of PI3K signaling activation are
signiﬁcantly increased and strongly correlated with the increased
rate of tumor initiation in a myr-p110α copy number-dependent
manner. These data demonstrated that higher levels of PI3K
activity induced by myr-p110α addition have profound effects on
tumor initiation. In addition, our results showed that the biological
activity of PI3K signaling can be further activated by cooperation
of myr-p110α with KrasG12D mutation. Our data from the use of
breast tumor cells also determined that the addition of myr-p110α
allele into p53ﬂ/ﬂ;KrasG12D mutants facilitates engraftment in the
lungs, as an assay of metastatic potential, in a copy numberdependent manner. Overall, our ﬁndings provide experimental
evidence that PI3K activating mutations associated with increased
Oncogenesis (2016), 1 – 11
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Figure 6. Addition of one copy of myr-p110α into p53ﬂ/ﬂ;KrasG12D double mutants accelerates tumor development in lung. (a) Hematoxylin and
eosin (H&E) staining of lungs dissected from p53ﬂ/ﬂ;KrasG12D and p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice 52 days post Ad-Cre virus injection. Pictures
of H&E staining were taken with × 40 magniﬁcation and are representative. Scale bar represents 1 mm and indicates scale for all images.
(b) Bar graphs describing the weight of lung divided by body weight, 52 days after Ad-Cre virus injection. Error bars are the mean ± s.e.m.
Two-tailed unpaired Student’s t-test was used for statistical analysis. ***P o0.001. (c) Kaplan–Meier survival curve scoring mice showing
symptoms from lung tumor growth deﬁned as any symptoms associated with illness. Log-rank (Mantel–Cox) test was used for statistical
analysis. ***Po 0.001. Data in b and c are representative of three independent experiments using n = 5–6 per group.

PI3K signaling activity accelerate the rate of tumor initiation and
increase potential for metastasis.
Although p53ﬂ/ﬂ;KrasG12D;myr-p110αwt/ﬂ mice did not have
increased growth rates of breast tumors as compared with p53ﬂ/ﬂ;
KrasG12D mice once tumors had developed, there was a modest
but signiﬁcant increase in the growth rate of tumors following
initiation in p53ﬂ/ﬂ;KrasG12D mice with two copies of myr-p110α as
compared with p53ﬂ/ﬂ;KrasG12D mice and p53ﬂ/ﬂ;KrasG12Dmice with
one copy of myr-p110α. One potential interpretation for these
results is that sufﬁciently high levels of PI3K/AKT signaling
activation also contribute to tumor growth rate.

levels of PI3K signaling might have a distinct impact on
developing carcinoma phenotypes in humans. As the histological
phenotype of tumors with two copies of myr-p110α was quite
different than tumors with one copy, the increased growth rate
induced by two copies could be attributed to the difference in
tumor type generated by one versus two copies. One limitation of
our study is that we did not deﬁne the relation between the
spatial expression levels of myr-p110α or resulting p-AKT levels
and histological features within the speciﬁc tumor areas.
Additional studies are warranted to further evaluate this
association between PI3K activity and tumor differentiation.

Impact of dosage of constitutively active PI3K on breast tumor
phenotype
In our study, the addition of myr-p110α allele into p53ﬂ/ﬂ;KrasG12D
or p53ﬂ/ﬂ that resulted in signiﬁcantly increased PI3K/AKT signaling
activation generated a carcinoma histologic phenotype in a
myr-p110α copy number-dependent manner. The resulting
tumors induced by the addition of myr-p110α allele resembled
those that are commonly seen in the majority of human breast
cancer. This was evident by the morphology of the invasive
carcinoma, as well as by the increased presence of DCIS and
benign epithelial proliferations. Thus, these ﬁndings suggest that

Value of triple mutant transgenic mice for human cancer model
The value of genetically modiﬁed mouse models for cancer
studies lies in the uniformity of the mouse background,
the speed of cancer development enabling practical studies, and
the similarity to human disease both genetically and histopathologically. The inherent heterogeneity of human breast cancer with
variant histopathologic features even within a single tumor33,34
creates an enormous challenge for understanding exact
mechanisms of disease pathology. Our goal was to develop a
breast cancer model that recapitulates the most common
histopathological breast tumors, is temporally inducible and
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spatially controlled by the experimenter, and initiates and
develops rapidly to facilitate practical experimentation.
Current mouse breast tumors driven by PI3KCA activating
mutations mimic histopathologic phenotypes observed in human
breast cancers;17–20,35 however, these single genetic mutation
mouse models can take a year to develop breast tumors.
Our mouse model that combines one or two copies of
myr-p110α with p53ﬂ/ﬂ;KrasG12D can resemble human breast cancer
subtypes, as well as develop tumors early and grow quickly,
leading to a shortened experimental timeline from tumor
initiation to end stage.
Spontaneous additional mutations have been demonstrated to
accumulate along with epigenetic events resulting in an increased
level of genetic complexity in human cancer.36 The mouse model
reported here is unique in that it harbors a PI3KCA (p110α)
oncogene, which is frequently mutated in many human cancers,3,6
along with the tumor suppressor gene p53 deletion and a
well-known oncogene, KrasG12D. These mutations are repeatedly
altered in human cancers, so they represent relevant genetic
alterations that can be used in developing models to closely
mimic the pathological and biochemical features of cancers. In
addition, this new mouse model is also able to rapidly generate
cancers in other tissues by the application of Cre-recombinase
with adenovirus as demonstrated by lung cancer generation, and
it will be of scientiﬁc value to utilize this model for studying other
tumor types. As the mutations require Cre-recombinase for
manifestation, the triple mutation mouse lines can be maintained
easily since breeding is not affected.
In summary, this novel triple mutation model system (1) is an
autochthonous genetic model of human cancer, (2) provides
controlled inducible expression of genetic changes spatially and
temporally, (3) induces tumor subtypes matched histologically to
human breast tumors, and (4) develops tumors very rapidly. The
characteristics outlined should make this new genetically modiﬁed
mouse model of signiﬁcant value for understanding the molecular
mechanisms underlying development of various tumors.
MATERIALS AND METHODS
Generation of experimental transgenic mice
The transgenic Cre-inducible myristoylated-p110α mice on C57BL/6
backgrounds were generated22 and intercrossed with Cre-inducible mice
carrying either only p53 deletion homozygote (p53ﬂ/ﬂ, which deletes exon 2
to exon 10 leading to null alleles of p53 upon Cre-mediated excision)37 or
p53ﬂ/ﬂ and KrasG12D mutations29 (p53ﬂ/ﬂ;KrasG12D, intercrossed) on C57BL/6
backgrounds. Conditional mutant mice with various genotypes were
obtained and genotyped by PCR. The animal study protocol was reviewed
and approved by the institutional animal care and use committee of Geisel
School of Medicine at Dartmouth.

In vivo intraductal delivery of Adeno-Cre virus into mammary duct
Six- to eight-week-old virgin females were anesthetized by isoﬂuorane/
oxygen inhalation. The calcium phosphate precipitate containing 2.5 × 107
plaque-forming unit of Ad-Cre virus was injected into the teat canal of
fourth inguinal mammary duct using a Hamilton syringe with 33-G
needle.23 Mice were monitored daily for a palpable/visible tumor
formation. Tumor surface area was calculated by the formula: tumor size
(mm2) = length (mm) × width (mm), after caliper measurements.

Hematoxylin and eosin stain
Parafﬁn-embedded tissues after ﬁxation with 10% buffered formalin
(15740-01, Electron Microscopy Sciences, Hatﬁeld, PA, USA) were sectioned
at 6 μm. Deparafﬁnized sections were stained with hematoxylin and eosin
following the manufacturer’s protocol and mounted with Permount
(SP15-100, Fisher Scientiﬁc, Grand Island, NY, USA). Images were obtained
on an Olympus BX5.1 or BX4 microscope (Olympus, Waltham, MA, USA),
and captured using Image Pro software (Media Cybernetics, Rockville,
MD, USA).

Immunohistochemistry
Tumors were parafﬁn-embedded after ﬁxation in 10% buffered formalin
and sectioned at 6 μm. Sections were immunostained using standard
manufacturer’s protocols at the Dartmouth-Hitchcock Medical Center
Laboratory for Clinical Genomics and Advanced Technology with the
following antibodies: anti-CK5 (ab52635, Abcam, Cambridge, MA, USA),
anti-CK14 (RB-9020, Thermo Scientiﬁc, Fremont, CA, USA), anti-CK8
(ab53280, Abcam), anti-estrogen receptor alpha (SC-542, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-PR (RM-9102, Thermo Scientiﬁc),
anti-HER2/neu (MA5-15050, Thermo Scientiﬁc) and anti-vimentin (ab92547,
Abcam). Images were obtained using an Olympus BX5.1 or BX41
microscope and Image Pro software. Hematoxylin and eosin-stained and
immunostained slides were reviewed by a breast pathologist (JDM).

Protein preparation and western blot
Mammary tumors were lysed in ice-cold lysis buffer containing 50 mM
Tris–HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM NaVO4,
protease inhibitor (11836170001, Roche, Indianapolis, IN, USA) and
phosphatase inhibitor cocktail (P5726, Sigma-Aldrich, St Louis, MO, USA).
An amount of 20 μg proteins were separated on 9% SDS-polyacrylamide
gel electrophoresis gels and transferred to Immobilon-P membranes
(IPVH00010, Millipore, Darmstadt, Germany). According to the standard
protocols, the membranes were immunoblotted with following primary
antibodies: anti-p110α (4249, Cell Signaling Technology, Beverley, CA,
USA), anti-AKT1/2/3 (4691, Cell Signaling Technology), anti-p-AKT1/2/3
Ser473 (4060, Cell Signaling Technology), anti-p85α (sc-1637, Santa Cruz
Biotechnology), anti-PTEN (9559, Cell Signaling Technology), anti-p-PTEN
Ser380/Thr382/Thr383 (sc-101789, Santa Cruz Biotechnology), anti-GFP
(sc-9996, Santa Cruz Biotechnology) and horseradish peroxidaseconjugated anti-β-Actin (ab49900, Abcam). This was followed by
incubation with horseradish peroxidase-conjugated anti-rabbit (sc-2313,
Santa Cruz Biotechnology) or anti-mouse (sc-2060, Santa Cruz
Biotechnology) secondary antibody. Immunoreactive proteins were
detected by chemiluminescence ECL (sc-2048, Santa Cruz Biotechnology),
quantiﬁed using ImageLab software (Bio-Rad, Hercules, CA, USA) and
normalized with respect to β-actin expression.

Preparation of breast tumor cells and assay of metastatic potential
The cells were derived from culturing large numbers of dissociated breast
tumor cells in complete DMEM over several passages (less than ﬁve). The
metastatic potential of breast tumor cells was tested by intravenous
injection of 0.5 × 106 cells into the tail vein of syngeneic mice. The number
of tumor lesions over 1.5 mm in diameter on the lungs was counted
macroscopically after stained with 0.05% 1,9-dimethyl-methylene blue.

in vivo intratracheal delivery of Adeno-Cre virus into the lung
Six- to eight-week-old mice were anesthetized by intraperitoneal injection
of avertin (0.3 mg/g body weight). The Exel Safelet IV catheter was inserted
into the mouth and slid into the trachea, and the calcium phosphate
precipitate containing 2.5 × 107 plaque-forming unit of Ad-Cre virus was
injected through the opening of the catheter using a 0.5-ml syringe. Mice
were monitored for clinical symptoms of poor health, such as lethargy,
panting/respiratory distress and/or decreased mobility.

Mouse embryonic ﬁbroblasts (MEFs) preparation
MEFs were derived and cultured as previously described.22

Ad-Cre virus infection of MEFs
60–70% conﬂuent MEFs at passage number 2–3 were infected at
multiplicity of infection 100:1 (virus:cell) with adenovirus-expressing
Cre-recombinase (Ad5CMVCre, University of Iowa, Gene Transfer Vector
Core) in DMEM supplemented with 2% fetal bovine serum for 6 h. The
infection efﬁciency was conﬁrmed by ﬂow cytometry of eGFP-positive cells
to ensure that 485% cells expressed the myr-p110α.

Anchorage-independent cell growth assay in vitro
A total of 2000 pooled transfected MEFs were resuspended in a top layer of
0.35% agar-containing DMEM and plated onto a bottom layer of 0.5%
agar-containing DMEM in 12-well plates in triplicate. After 30 days,
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the colonies were stained with 0.005% crystal violet and counted
macroscopically. Minimum diameter of the colonies was 50 μm.

In vivo tumor formation assay
Total 1 × 106 pooled transfected MEFs were injected intradermally into
six- to eight-week-old immunocompromised NOD/scid IL2 gamma chain
KO (NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice. Mice were monitored daily
to detect a palpable/visible tumor.

Statistical analysis
Two-tailed unpaired Student’s t-test and the Mann–Whitney test were used
for comparison between experimental groups analyzed for anchorageindependent cell growth assay, metastatic potential assay and
western blots. For experiments involving a comparison between three or
more distinct groups, one-way analysis of variance test was used.
Statistics were calculated as non-parametric Log-rank (Mantel–Cox)
analysis of Kaplan–Meier for censored survival and tumor-free data. Data
analysis was performed using Prism 5.0 software (GraphPad software,
La Jolla, CA, USA). Graphs in ﬁgures denoted statistical signiﬁcance
of *Po0.05, **Po0.01, and ***Po0.001. P40.05 was considered
non-signiﬁcant (ns).
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